Parvovirus B19 Enters the Bloodstream
A short placeholder sentence on early B19 infection.
- 4–14: Incubation period (days typical)
- Day 6–10: Peak viremia (placeholder value)
- Erythroid: Target cell (precursor cells)
- Respiratory: Transmission (droplets, blood)
Viral entry
Placeholder sentence on how B19 enters the body.
Placeholder highlight on early viremia window.
Red cell impact
Placeholder sentence on erythroid precursor infection.
Contagious window
Placeholder sentence noting peak contagion before rash.
Slapped-Cheek Rash Appears
A short placeholder sentence on the classic facial rash.
- Day 4–7: Rash onset (after exposure)
- Bright red: Appearance (both cheeks)
- Low now: Contagion (placeholder value)
- 2–4 days: Duration (placeholder value)
Classic sign
Placeholder sentence on the slapped-cheek appearance.
Placeholder highlight on non-contagious status post-rash.
Immune response
Placeholder sentence on immune clearance of virus.
Diagnosis clue
Placeholder sentence on clinical recognition of rash.
Lacy Reticular Rash Spreads
A short placeholder sentence on lacy rash progression.
- Lace-like: Pattern (reticular pattern)
- Trunk/limbs: Spread (placeholder value)
- Heat/sun: Trigger flare (placeholder value)
- 1–3 weeks: Resolution (placeholder value)
Rash pattern
Placeholder sentence on the reticular lace appearance.
Placeholder highlight on rash coming and going.
Symptom overlap
Placeholder sentence on joint pain in adults.
Self-limited course
Placeholder sentence noting typical full recovery.
Pregnant Contact Exposure Risk
A short placeholder sentence on maternal exposure risk.
- ~50%: Maternal infection risk (if seronegative)
- ~30%: Fetal transmission (placeholder value)
- <20 wks: Highest-risk window (gestation)
- ~5–10%: Severe outcome (placeholder value)
Exposure pathway
Placeholder sentence on household or classroom exposure.
Placeholder highlight on early-pregnancy risk window.
Placental crossing
Placeholder sentence on virus crossing the placenta.
Serology testing
Placeholder sentence on maternal IgM/IgG testing.
Fetal Hydrops and Anemia Monitoring
A short placeholder sentence on fetal monitoring needs.
- Doppler US: Monitoring tool (MCA velocity)
- 8–12 wks: Monitoring duration (post-exposure)
- Elevated: Hydrops risk (placeholder value)
- IUT: Treatment option (intrauterine transfusion)
Hydrops fetalis
Placeholder sentence on fluid accumulation signs.
Placeholder highlight on serial ultrasound benefit.
Anemia detection
Placeholder sentence on MCA Doppler anemia screening.
Outcome
Placeholder sentence noting most cases resolve well.